 This study will assess the quality of life in renal transplant recipients who require a reduced dose of mycophenolate mofetil MMF because of gastrointestinal GI side effects and will also access the relationship between mycophenolic acid MPA dose in those patients receiving enteric-coated mycophenolate sodium formulationEC-MPS. 